You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,582,823


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,582,823
Title: Methods of treating bacterial inflammation and granulocytopoiesis by administering human pluripotent granulocyte colony-stimulating factor
Abstract:Disclosed are novel polypeptides possessing part or all of the primary structural conformation and one or more of the biological properties of a mammalian (e.g., human) pluripotent granulocyte colony-stimulating factor (\"hpG-CSF\") which are characterized in preferred forms by being the product of procaryotic or eucaryotic host expression of an exogenous DNA sequence. Sequences coding for part or all of the sequence of amino acid residues of hpG-CSF or for analogs thereof may be incorporated into autonomously replicating plasmid or viral vectors employed to transform or transfect suitable procaryotic or eucaryotic host cells such as bacteria, yeast or vertebrate cells in culture. Products of expression of the DNA sequences display, e.g., the physical and immunological properties and in vitro biological activities of isolates of hpG-CSF derived from natural sources. Disclosed also are chemically synthesized polypeptides sharing the biochemical and immunological properties of hpG-CSF.
Inventor(s): Souza; Lawrence M. (Thousand Oaks, CA)
Assignee: Amgen Inc. (Thousand Oaks, CA)
Application Number:08/452,135
Patent Claims:1. A method for treating a mammal for bacterial inflammation comprising an effective amount of a hpG-CSF polypeptide having an amino acid sequence selected from the group consisting of: ##STR18## and analogs thereof wherein one or more of the cysteine residues at positions 17, 36, 42, 64 and 74 are replaced by serine.

2. A method for providing granulocytopoietic therapy to a mammal comprising administering an effective amount of a hpG-CSF polypeptide having an amino acid sequence selected from the group consisting of:

and

analogs thereof wherein one or more cysteines residues located at positions 17, 36, 42, 64 and 74 are replaced by serine.

3. A method of claim 2 wherein said therapy is in conjunction with chemotherapy.

4. A method of claim 2 wherein said therapy is in conjunction with radiation therapy.

5. A method of claim 2 wherein said therapy is in conjunction with removal of blood progenitor cells.

Details for Patent 5,582,823

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 02/20/1991 ⤷  Try a Trial 2013-12-10
Amgen, Inc. NEUPOGEN filgrastim Injection 103353 06/28/2000 ⤷  Try a Trial 2013-12-10
Amgen, Inc. NEULASTA pegfilgrastim Injection 125031 01/31/2002 ⤷  Try a Trial 2013-12-10
Amgen, Inc. NEULASTA ONPRO pegfilgrastim Injection 125031 12/23/2014 ⤷  Try a Trial 2013-12-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 5,582,823

Country Patent Number Estimated Expiration
South Africa 866412 ⤷  Try a Trial
World Intellectual Property Organization (WIPO) 8701132 ⤷  Try a Trial
United States of America 6716606 ⤷  Try a Trial
United States of America 6379661 ⤷  Try a Trial
United States of America 6004548 ⤷  Try a Trial
United States of America 5830705 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.